Jason A. Chesney
Medical Practice at Jackson St, Louisville, KY
License number
Kentucky 37726
Issued Date
Mar 27, 2003
Expiration Date
Feb 28, 2018
Category
Hematology/Oncology
Type
Hospital Based
Address
Address
529 S Jackson St, Louisville, KY 40202
Education
University of Minnesota Medical School, Minneapolis, 1998
Phone
(502) 852-3402 (Work)
Personal information
See more information about Jason A. Chesney at radaris.comName
Address
Phone
324 E Main St UNIT 204, Louisville, KY 40202
Louisville, KY
529 Jackson St, Louisville, KY 40202
604 S 3Rd St #611, Louisville, KY 40202
951 Baxter Ave, Louisville, KY 40204
Organization information
See more information about Jason A. Chesney at bizstanding.comJason Chesney MD,PHD
529 S Jackson St, Louisville, KY 40202
Industry:
Oncology, Internist
Phone:
(502) 562-4370 (Phone)
Jason Alan Chesney
Professional information
Dr. Jason Chesney, Louisville KY - MD (Doctor of Medicine)
Specialties:
Medical Oncology, Hematology, Internal Medicine
Address:
James Graham Brown Cancer Center
529 S Jackson St, Louisville 40202
(502) 562-4369 (Phone)
529 S Jackson St, Louisville 40202
(502) 562-4369 (Phone)
Certifications:
Internal Medicine, 2001
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
James Graham Brown Cancer Center
529 S Jackson St, Louisville 40202
University of Louisville Hospital
530 South Jackson St, Louisville 40202
Norton Audubon Hospital
1 Audubon Plaza Dr, Louisville 40217
Norton Hospital
200 East Chestnut St, Louisville 40202
529 S Jackson St, Louisville 40202
University of Louisville Hospital
530 South Jackson St, Louisville 40202
Norton Audubon Hospital
1 Audubon Plaza Dr, Louisville 40217
Norton Hospital
200 East Chestnut St, Louisville 40202
Philosophy:
At University of Louisville Physicians, we serve our patients and their families with compassionate, personalized attention and are dedicated to providing the most innovative, advanced health care in the region.
Education:
Medical School
University Of Minnesota Medical School
Graduated: 1998
Cornell University
University Of Minnesota Medical School
Graduated: 1998
Cornell University
Jason Chesney, Louisville KY
Work:
James Graham Brown Cancer Center
529 S Jackson St, Louisville, KY 40202 Robley Rex VA Medical Center
800 Zorn Ave, Louisville, KY 40206
529 S Jackson St, Louisville, KY 40202 Robley Rex VA Medical Center
800 Zorn Ave, Louisville, KY 40206
Jason A Chesney, Louisville KY
Specialties:
Internist
Address:
501 E Broadway, Louisville, KY 40202
529 S Jackson St, Louisville, KY 40202
529 S Jackson St, Louisville, KY 40202
Education:
Doctor of Medicine*
Small Molecule Choline Kinase Inhibitors, Screening Assays, And Methods For Treatment Of Neoplastic Disorders
US Patent:
2013001, Jan 10, 2013
Filed:
May 12, 2012
Appl. No.:
13/470274
Inventors:
Brian Clem - Louisville KY, US
Sucheta Telang - Louisville KY, US
John Trent - Louisville KY, US
Jason Chesney - Louisville KY, US
Pooran Chand - Birmingham AL, US
Gilles Tapolsky - Louisville KY, US
Sucheta Telang - Louisville KY, US
John Trent - Louisville KY, US
Jason Chesney - Louisville KY, US
Pooran Chand - Birmingham AL, US
Gilles Tapolsky - Louisville KY, US
Assignee:
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - Louisville KY
International Classification:
A61K 31/4196, A61K 31/216, G06F 19/16, C07C 69/736, C07C 69/157, A61P 35/00, A61K 31/222, C07D 249/12
US Classification:
514384, 514543, 514546, 514510, 5482644, 560 61, 560130, 703 11
Abstract:
Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided.
Pfkb3 Inhibitor For The Treatment Of A Proliferative Cancer
US Patent:
8088385, Jan 3, 2012
Filed:
Jun 18, 2008
Appl. No.:
12/141751
Inventors:
Jason Chesney - Louisville KY, US
John O. Trent - Louisville KY, US
Sucheta Telang - Louisville KY, US
Brian Clem - Louisville KY, US
Jason Meier - Louisville KY, US
John O. Trent - Louisville KY, US
Sucheta Telang - Louisville KY, US
Brian Clem - Louisville KY, US
Jason Meier - Louisville KY, US
Assignee:
University of Louisville Research Foundation Inc. - Louisville KY
International Classification:
A01N 43/40, A61K 31/44, A61K 39/395
US Classification:
4241741, 514332
Abstract:
A methods and compounds for inhibiting 6-phosphofructo-2-kinase /fructose-2,6-bisphosphatase 3 (PFKFB3) are described. Also described are methods of inhibiting cell proliferation, treating cancer, and screening compounds to determine their ability to inhibit PFKFB3.
Small-Molecule Choline Kinase Inhibitors As Anti-Cancer Therapeutics
US Patent:
2011025, Oct 20, 2011
Filed:
Dec 22, 2010
Appl. No.:
12/975631
Inventors:
Pooran Chand - Birmingham AL, US
Jason A. Chesney - Louisville KY, US
Brian F. Clem - Louisville KY, US
Gilles H. Tapolsky - Louisville KY, US
Sucheta Telang - Louisville KY, US
John O. Trent - Louisville KY, US
Jason A. Chesney - Louisville KY, US
Brian F. Clem - Louisville KY, US
Gilles H. Tapolsky - Louisville KY, US
Sucheta Telang - Louisville KY, US
John O. Trent - Louisville KY, US
Assignee:
ADVANCED CANCER THERAPEUTICS, LLC - Louisville KY
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - Louisville KY
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - Louisville KY
International Classification:
A61K 31/506, C07D 417/12, C07D 401/12, C07D 401/04, C07D 403/12, A61P 35/00, A61K 31/427, A61K 31/4439, A61K 31/4709, A61K 31/428, A61K 31/454, C12N 9/99, C07D 249/12, A61K 31/4196
US Classification:
514275, 5482644, 548195, 5462724, 546167, 548163, 544331, 546210, 514383, 514371, 514341, 514314, 514367, 514326, 435184
Abstract:
Small molecule choline kinase inhibitors having the following formula:are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.
Pfkfb4 Inhibitors And Methods Of Using The Same
US Patent:
8283332, Oct 9, 2012
Filed:
Apr 16, 2010
Appl. No.:
12/761773
Inventors:
Sucheta Telang - Louisville KY, US
Jason Chesney - Louisville KY, US
Jason Chesney - Louisville KY, US
Assignee:
University of Louisville Research Foundation, Inc. - Louisville KY
International Classification:
A61K 48/00
US Classification:
514 44R
Abstract:
Methods of reducing expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) and methods of treating a cancer in a cell are provided, the methods including contacting a cell with an effective amount of a PFKFB4 inhibitor. Short hairpin RNA (shRNA) and small interfering RNA (siRNA) inhibitors of PFKFB4 and their methods of use are also provided.
Small Molecule Choline Kinase Inhibitors, Screening Assays, And Methods For Safe And Effective Treatment Of Neoplastic Disorders
US Patent:
2011021, Sep 1, 2011
Filed:
Jun 28, 2010
Appl. No.:
12/824680
Inventors:
BRIAN CLEM - LOUISVILLE KY, US
SUCHETA TELANG - LOUISVILLE KY, US
JOHN TRENT - LOUISVILLE KY, US
JASON CHESNEY - LOUISVILLE KY, US
POORAN CHAND - BIRMINGHAM AL, US
GILLES TAPOLSKY - LOUISVILLE KY, US
SUCHETA TELANG - LOUISVILLE KY, US
JOHN TRENT - LOUISVILLE KY, US
JASON CHESNEY - LOUISVILLE KY, US
POORAN CHAND - BIRMINGHAM AL, US
GILLES TAPOLSKY - LOUISVILLE KY, US
International Classification:
A61K 31/4709, A61K 31/426, A61K 31/428, A61K 31/427, A61K 31/4196, A61K 31/4166, A61K 31/216, A61K 31/24, A61K 31/165, C07D 401/04, C07D 401/12, C07D 417/12, C07D 277/24, C07D 249/12, C07D 233/78, C07C 323/62, C07C 69/736, C07C 235/34, A61P 35/00, G06G 7/58
US Classification:
514314, 514365, 514367, 514371, 514384, 514389, 514391, 514510, 514534, 514543, 514622, 546167, 546171, 548178, 548195, 548204, 5482644, 5483167, 560 9, 560 61, 564182, 703 11
Abstract:
Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided.
Family Of Pfkfb3 Inhibitors With Anti-Neoplastic Activities
US Patent:
8557823, Oct 15, 2013
Filed:
Nov 30, 2011
Appl. No.:
13/307552
Inventors:
Gilles Tapolsky - Louisville KY, US
Pooran Chand - Birmingham AL, US
John O. Trent - Louisville KY, US
Sucheta Telang - Louisville KY, US
Brian F. Clem - Louisville KY, US
Jason A. Chesney - Louisville KY, US
Pooran Chand - Birmingham AL, US
John O. Trent - Louisville KY, US
Sucheta Telang - Louisville KY, US
Brian F. Clem - Louisville KY, US
Jason A. Chesney - Louisville KY, US
Assignee:
Advanced Cancer Therapeutics, LLC - Louisville KY
University of Louisville Research Foundation, Inc. - Louisville KY
University of Louisville Research Foundation, Inc. - Louisville KY
International Classification:
A01N 43/42, A61K 31/47, A61K 31/497, C07D 215/12, C07D 215/14
US Classification:
51425308, 514311, 514314, 546174
Abstract:
A methods and compounds for inhibiting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) are described. Also described are methods of inhibiting cell proliferation, treating cancer, and screening compounds to determine their ability to inhibit PFKFB3.
T Cell Depleting Compositions Useful For Treating Cancer
US Patent:
2010032, Dec 23, 2010
Filed:
Jun 20, 2008
Appl. No.:
12/665795
Inventors:
Jason Chesney - Louisville KY, US
Assignee:
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. - Louisville KY
International Classification:
A61K 38/20, A61K 39/395, A61K 31/519, A61K 31/675, A61K 31/137, A61K 31/255, A61K 31/7076, A61K 39/00, A61P 35/00, A61P 37/04
US Classification:
424 852, 4241731, 5142621, 514 90, 514646, 514517, 514 47, 4241841
Abstract:
The presently-disclosed subject matter provides methods and compositions for treating or reducing the risk of recurrence of a cancer in a subject. The methods comprise administering an effective amount of a T cell depleting composition to the subject to thereby treat the cancer.